PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Non-Small Cell Lung Cancer.

PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Malignant Pleural Effusion.

Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer Malignant pleural effusion (MPE) is common in ...

The connection between systemic immune reactions in the blood and local immune reactions in pleural effusions remains unclear. This study provides the first comprehensive immunological ...

On Thursday, however, Keros reported that it had detected “unanticipated” cases of pericardial effusion in the study, a complication that is characterized as the abnormal accumulation of fluid around ...